Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors Poster Population Pharmacokinetic Analysis of DS-8201a, A HER2-Targeting Antibody-Drug Conjugate, in Patients with HER2-Positive Breast Cancer or Other Solid Tumors CertaraMay 2, 2019
Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models Poster Simulating the Impact of the Interplay Between CYP2C19 Polymorphisms and Ethnicity on Response to Clopidogrel, Using PBPK-PD Models CertaraApril 22, 2019
Development of a Physiologically-Based Pharmacokinetic Model for Topical Lidocaine in Order to Predict Systemic Absorption in Healthy Volunteers, Geriatrics, and Pediatrics Poster Development of a Physiologically-Based Pharmacokinetic Model for Topical Lidocaine in Order to Predict Systemic Absorption in Healthy Volunteers, Geriatrics, and Pediatrics CertaraApril 22, 2019
Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients Poster Exposure-Response Analyses to Support Dose Justification of DS-8201A, A HER2-Targeting Antibody-Drug Conjugate, in HER2-Positive Breast Cancer Patients CertaraApril 22, 2019
Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies Poster Relationship of Ivosidenib Plasma Concentration to Heart Rate-Corrected QT Interval in Patients with IDH1-Mutant Advanced Hematologic Malignancies CertaraApril 22, 2019
Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation Poster Validation of the Pharmacokinetic/Pharmacodynamic Model Used for Dose Selection of Andexanet Alfa for Reversal of Anticoagulation CertaraApril 22, 2019
Real World Evidence Marches Forward in Drug Development Blog Real World Evidence Marches Forward in Drug Development The end of 2018 ushered in a flurry of new regulatory guidance and sponsor enthusiasm…CertaraMarch 20, 2019
How to Perform IVIVC for Extremely Long Acting Drugs On-Demand Webinar How to Perform IVIVC for Extremely Long Acting Drugs Watch this webinar to learn how to use in vitro and in vivo models to…CertaraFebruary 22, 2019
Managing Immunogenicity Using Quantitative Systems Pharmacology Blog Managing Immunogenicity Using Quantitative Systems Pharmacology The Challenge of Immunogenicity in Biologics Drug Development Biologic drug development is a rapidly evolving…CertaraFebruary 22, 2019
PBPK’s Pivotal Role in Modern Drug Development: Busting Common Myths and Misconceptions White Paper PBPK’s Pivotal Role in Modern Drug Development: Busting Common Myths and Misconceptions This white paper addresses common PBPK myths and misconceptions and demonstrates how this approach is…CertaraFebruary 4, 2019